Rebounding, if not reborn Oxford Molecular (LSE:OMG) the enabling technology company, gained 16.5p (33 percent) to 66p, continuing its three-week rise since Townsley & Co. issued a "buy" on the company. OMG has a market cap of £57.5 million ($92 million).

Scotia (LSE:SOH), rose 9.5p to 115p on Friday after Investors Chronicle, a publication for retail investors, speculated that the company is due to close a drug delivery deal. SOH was up 13.5p (13 percent) on the week to a market cap of £90.5 million ($145 million).

Celsis (LSE:CEL) gained 3p (15 percent) to close at 23p. The company announced French approval for its RapiScreen system that screens for microbial contamination in pharmaceutical products. CEL's market cap is £23.6 million ($38 million).

Hard to please

Biogen (BGEN) met the consensus EPS estimate of $0.58, and investors rewarded it by taking back $5.563 to $114.438 on 3.2 million shares on Friday. The stock had run up over the first four days of the week in anticipation of Thursday's post-market earnings announcement. Despite profit-taking and word on the Street that some investors and analysts were betting that BGEN would beat the EPS number, the stock still gained $0.938 on the week. Sales of BGEN's Avonex multiple sclerosis therapy hit $131.3 million in the first quarter, up from $76.1 million in the 1998 period. BGEN said more than 60,000 patients are on Avonex therapy worldwide.